Home › NDC Lookup › Ingredients › Prednisone › 00054-9817-25
PredniSONE 10 mg Tablet, 100-count — NDC 00054-9817-25 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

PredniSONE 10 mg Tablet, 100-count — NDC 0054-9817-25 (Billing 00054-9817-25)

by Hikma Pharmaceuticals USA Inc. · 100 TABLET in 1 BOTTLE

This is a package of 100 tablets of PredniSONE 10 mg Tablet from Hikma Pharmaceuticals USA Inc., marketed since Mar 2020 and currently FDA-listed; retail pharmacies pay about $0.0533 per tablet (NADAC).

NDC 00054-9817-25
🏷️ FDA NDC (as labeled) 0054-9817-25 billing pads the labeler segment with a zero
This package
Contains100-count Cost per ea$0.0533 NADAC Per package$5.33 / 100 tablets Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.2851/unit · Part D plans $0.2837/unit — full pricing hub ↓
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

NDC database record

One package, one record: these facts belong to NDC 0054-9817-25 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0054 labeler · 9817 product · 25 package
Package marketed since
Mar 23, 2020
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Billing quantity
100 EA per package
Barcode (UPC)
0300549817252, 0300549828258, 0300549818259
Medicaid fills, this package
33,818 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0054-9817-25
Product NDC 0054-9817
11-digit billing NDC 00054981725
NCPDP billing unit EA — each (per item)
RxCUI 198145, 312615, 312617
UNII VB0R961HZT
UPC 0300549817252, 0300549828258, 0300549818259
Application # ANDA080352
SPL Set ID 263ed4fa-3c29-4abb-9cb1-bc016bd34a05
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2020-03-23
Route ORAL
Dosage form TABLET
Substance PREDNISONE
TE code (Orange Book) AB · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 22100045000320
GPI class predniSONE
GCN Seq No 006749
GCN 27172
HICL code 002879
Ingredient (HICL) Prednisone
HIC1 code P
Therapeutic class — broad (HIC1) Endocrine System
HIC2 code P5
Therapeutic class — intermediate (HIC2) Adrenocortical Hormones
HIC3 code P5A
Therapeutic class — specific (HIC3) Glucocorticoids
AHFS code 68:04.00.00
AHFS class Adrenals
FDB label name PREDNISONE 10 MG TABLET
FDB brand name Prednisone
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 006749
  • GCN: 27172
  • GPI-14 (Medi-Span): 22100045000320
  • HICL (First Databank): 002879
  • AHFS class code: 68:04.00.00
  • RxCUI (RxNorm): 198145
Why two NDCs? The FDA registers this code as 0054-9817-25 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00054-9817-25. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids acting locally, Glucocorticoids
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name PREDNISONE 10 MG TABLET Ingredient Prednisone
📖 What it is MedlinePlus · NLM

Prednisone is used alone or with other medications to treat the symptoms of low corticosteroid levels (lack of certain substances that are usually produced by the body and are needed for normal body functioning). Prednisone is also used to treat other conditions in patients with normal corticosteroid levels. These conditions include certain types of arthritis; severe allergic reactions; multiple sclerosis (a disease in which the nerves do not function properly); lupus (a disease in which the body attacks many of its own organs); and certain conditions that affect the lungs, skin, eyes, kidneys...

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It calms inflammation and lowers immune activity. It is used for allergies, arthritis, lupus, skin, gut, lung, eye and blood conditions, and more. Your prescriber chose it for your...
  • Take it with food or milk to protect your stomach. A once-daily dose is usually best in the morning. If you have delayed-release tablets, take them with food and swallow them whole...
  • No, not after long-term use. Your body may need time to restart its own steroid production. Your doctor will lower the dose gradually.
  • Bigger appetite, weight gain, trouble sleeping, mood swings and stomach upset are common. Call your doctor for signs of infection, black stools, severe stomach pain, vision changes...
📖 Read our full Prednisone guide →
8
Nutrient depletion considerations

Prednisone may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer eaPer package
Retail pharmacies payNADAC · weekly $0.053 $5.33 / 100 tablets
Medicaid paysCMS SDUD · 12 mo $0.2851 $28.51 / 100 tablets
Medicare drug plans payPart D · Q2 2026 $0.2837 $28.37 / 100 tablets
Medicare Part B allowsASP · J7512 $0.004 / J7512 unit —
NADAC price history (per ea) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.075 $0.053
▼ Down 29% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Billing & reimbursement

FDA NDC (as labeled)0054-9817-25
11-digit billing NDC00054-9817-25
Format4-4-2 as registered → padded to 5-4-2 for billing (zero added to the labeler segment)
HCPCS J-codeJ7512
DescriptorPREDNISONE, IMMEDIATE RELEASE OR DELAYED RELEASE, ORAL, 1 MG
Billing units / pkg10 units
How the units are derivedThis package is 100 EA; the HCPCS unit is 1 MG, so one package = 10 billing units.
Medicare Part B spend (2026 (Q1))$63,912 · 65,179 claims · $0.98 per claim (all NDCs under J7512)
Crosswalk sourcePDAC NDC-HCPCS crosswalk (DME MAC / DMEPOS)
Where does this data come from?
The HCPCS J-code crosswalk comes from the CMS ASP NDC-HCPCS crosswalk and the DMEPDAC (DME MAC) NDC-HCPCS crosswalk — free public CMS data. Billing units are derived from the code’s descriptor and the package amount.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00054-9817-25 You're viewing this 100 TABLET in 1 BOTTLE $0.0533 / ea $5.33 2020-03-23 — Active
00054-9817-29 0054-9817-29 Main listing 500 TABLET in 1 BOTTLE $0.0533 / ea $26.64 2020-03-23 — Active

You're viewing the smallest of 2 pack sizes for this product.

This pack has the lowest per-ea cost of the 2 priced pack sizes ($0.0533 NADAC).

This pack accounts for about 38% of this product's recent Medicaid fills; most go to the 500 tablets pack. See all packs ↓

Pack size FAQ

What quantity is in this package?
This is a 100-count package — 100 tablet in 1 bottle.
How does this package differ from NDC 00054-9817-29?
Both are PredniSONE 10 mg Tablet — the drug itself is identical. This page's package is the 100-count one, while NDC 00054-9817-29 is the 500 tablets package.
What NDC number is used to bill for this package of PredniSONE 10 mg Tablet?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
PredniSONE 10 mgthis 00054-9817-25 Hikma 100 tablets $0.053 AB Availability likely —
Prednisone 10 mg 00378-0641-01 Mylan 100 tablets $0.053 — Availability likely —
Prednisone 10 mg 00591-5442-01 Actavis 100 tablets $0.053 — Availability likely —
Prednisone 10 mg 00904-6923-61 Major 100 tablets $0.053 AB Availability likely —
Prednisone 10 mg 59651-0487-01 Aurobindo 100 tablets $0.053 AB Availability likely —
prednisone 10 mg 60219-1707-01 Amneal 100 tablets $0.053 AB Availability likely —
Prednisone 10 mg 60687-0134-01 American 100 tablets $0.053 AB Discontinued —
Prednisone 10 mg 60687-0914-01 American 100 tablets $0.053 AB Availability likely —
PredniSONE Tablets, USP, 10 mg 63561-0121-01 Granulation 100 tablets $0.053 AB Availability likely —
Prednisone 10 mg 70954-0059-10 ANI 100 tablets $0.053 AB Availability likely —
PredniSONE 10 mg 00054-0017-20 Hikma 100 tablets $0.060 AB FDA listed +14%
Prednisone 10 mg 00603-5338-15 Par 21 tablets $0.585 AB Availability likely +998%
prednisone 10 mg 00615-8440-05 NCS 15 tablets — AB FDA listed —
Prednisone 10 mg 10135-0777-01 Marlex 100 tablets — AB FDA listed —
PredniSONE 10 mg 42708-0045-21 QPharma, 21 tablets — — FDA listed —
Prednisone 10 mg 42708-0115-21 QPharma, 21 tablets — AB FDA listed —
prednisone 10 mg 42708-0166-21 QPharma 21 tablets — AB FDA listed —
Prednisone 10 mg 50090-3137-00 A-S 10 tablets — AB FDA listed —
Prednisone 10 mg 50090-5202-00 A-S 60 tablets — AB FDA listed —
Prednisone 10 mg 50090-7023-00 A-S 100 tablets — AB FDA listed —
Prednisone 10 mg 50090-7024-00 A-S 10 tablets — AB FDA listed —
Prednisone 10 mg 50090-7025-00 A-S 60 tablets — AB FDA listed —
prednisone 10 mg 50090-7218-00 A-S 10 tablets — AB FDA listed —
prednisone 10 mg 50090-7219-00 A-S 60 tablets — AB FDA listed —
prednisone 10 mg 50090-7369-00 A-S 10 tablets — AB FDA listed —
prednisone 10 mg 50090-7371-00 A-S 60 tablets — AB FDA listed —
Prednisone 10 mg 51407-0922-10 Golden 1000 tablets — — FDA listed —
Prednisone 10 mg 51655-0410-20 Northwind 20 tablets — AB FDA listed —
PredniSONE 10 mg 51655-0493-49 Northwind 42 tablets — — FDA listed —
Prednisone 10 mg 51655-0935-20 Northwind 20 tablets — — FDA listed —
Prednisone 10 mg 54348-0506-10 PharmPak, 10 tablets — AB FDA listed —
Prednisone 10 mg 55154-3564-00 Cardinal 10 tablets — AB FDA listed —
Prednisone 10 mg 63187-0037-05 Proficient 5 tablets — AB FDA listed —
Prednisone 10 mg 63187-0300-05 Proficient 5 tablets — AB FDA listed —
Prednisone 10 mg 63629-2257-01 Bryant 1000 tablets — AB FDA listed —
prednisone 10 mg 64380-0784-01 Strides 100 tablets — AB FDA listed —
Prednisone 10 mg 66267-0171-15 NuCare 15 tablets — AB FDA listed —
Prednisone 10 mg 66267-0812-10 NuCare 100 tablets — AB FDA listed —
prednisone 10 mg 67046-1579-03 Coupler 30 tablets — AB FDA listed —
Prednisone 10 mg 67296-0140-01 Redpharm 10 tablets — AB Discontinued —
Prednisone 10 mg 68071-2661-00 NuCare 10 tablets — AB FDA listed —
Prednisone 10 mg 68071-3641-01 NuCare 10 tablets — AB FDA listed —
Prednisone 10 mg 68071-3746-00 NuCare 10 tablets — AB FDA listed —
Prednisone 10 mg 68071-3821-03 NuCare 30 tablets — AB FDA listed —
prednisone 10 mg 68788-8166-02 Preferred 21 tablets — AB FDA listed —
prednisone 10 mg 70518-3476-00 REMEDYREPACK 21 tablets — AB Discontinued —
prednisone 10 mg 70518-4038-00 REMEDYREPACK 48 tablets — AB FDA listed —
PredniSONE 10 mg 70518-4191-01 REMEDYREPACK 30 tablets — — FDA listed —
prednisone 10 mg 70518-4354-00 REMEDYREPACK 30 tablets — AB FDA listed —
Prednisone 10 mg 70518-4560-00 REMEDYREPACK 18 tablets — AB FDA listed —
prednisone 10 mg 70518-4660-00 REMEDYREPACK 14 tablets — AB FDA listed —
Prednisone 10 mg 71205-0362-05 Proficient 5 tablets — AB FDA listed —
Prednisone 10 mg 71205-0421-10 Proficient 10 tablets — AB FDA listed —
prednisone 10 mg 71205-0729-10 Proficient 10 tablets — AB FDA listed —
prednisone 10 mg 71205-0818-05 Proficient 5 tablets — AB FDA listed —
Prednisone 10 mg 71335-0335-00 Bryant 10 tablets — AB Discontinued —
prednisone 10 mg 71335-2069-00 Bryant 10 tablets — AB FDA listed —
prednisone 10 mg 71335-2122-01 Bryant 5 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 71335-2736-00 Bryant 12 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 71335-2752-00 Bryant 10 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 71335-3044-01 Bryant 100 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 71335-3045-01 Bryant 1000 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 72162-2485-00 Bryant 1000 tablets — AB FDA listed —
Prednisone 10 mg 72189-0589-10 Direct_Rx 10 tablets — AB FDA listed —
Prednisone 10 mg 72789-0401-10 PD-Rx 10 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 72789-0475-01 PD-Rx 100 tablets — AB FDA listed —
PredniSONE Tablets, USP, 10 mg 72789-0513-10 PD-Rx 10 tablets — AB FDA listed —
Prednisone 10 mg 76420-0068-20 Asclemed 20 tablets — AB FDA listed —
prednisone 10 mg 76420-0412-00 Asclemed 1000 tablets — AB FDA listed —
Prednisone 10 mg 80425-0193-01 Advanced 21 tablets — AB FDA listed —
prednisone 10 mg 80425-0484-01 Advanced 21 tablets — AB FDA listed —
PredniSONE 10 mg 80425-0485-01 Advanced 21 tablets — — FDA listed —
Prednisone 10 mg 80425-0491-01 Advanced 21 tablets — AB FDA listed —
prednisone 10 mg 85766-0001-00 Sportpharm 1000 tablets — AB FDA listed —
Prednisone 10 mg 87063-0044-01 ASCLEMED 100 tablets — AB FDA listed —
Prednisone 10 mg 50090-1001-00 A-S 21 tablets — AB FDA listed —
Prednisone 10 mg 50090-1002-00 A-S 48 tablets — AB Discontinued —
PredniSONE 10 mg 55289-0330-05 PD-Rx 5 tablets — — FDA listed —
prednisone 10 mg 51655-0972-20 Northwind 20 tablets — AB FDA listed —
PredniSONE 10 mg 51655-0726-21 Northwind 21 tablets — AB FDA listed —
prednisone 10 mg 87441-0069-01 Unit 30 tablets — AB FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2020
On the market since
Mar 2020
📍
2026
Currently FDA-listed
6 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color White
ShapeRound
Imprint54;760
Size9 mm
ScoringScored — splits in 2
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII EWQ57Q8I5X
    Lactose monohydrate is a natural sugar derived from milk. It serves as a filler and binder in tablets and capsules, helping create the proper size, texture, and consistency of the medicine.
  • UNII 70097M6I30
    Magnesium stearate is a salt made from magnesium and stearic acid, a fatty substance. It's used in tablets and capsules as a lubricant and glidant to help ingredients flow smoothly during manufacturing and prevent sticking.
  • UNII OP1R32D61U
    Microcrystalline cellulose is a purified form of cellulose, a natural fiber from plant sources. It acts as a binder and filler in tablets and capsules, helping hold ingredients together and give the medicine its shape and size.
  • UNII 5856J3G2A2
    A starch-based powder made from potatoes and processed with sodium. It acts as a disintegrant, helping the tablet or capsule break apart quickly in the stomach so the medicine can be absorbed.
  • UNII O8232NY3SJ
    A plant-based carbohydrate derived from corn kernels. It acts as a filler to add bulk, a binder to hold ingredients together, and a disintegrant to help the tablet break apart in your stomach for absorption.

5 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerHikma Pharmaceuticals USA Inc.
Application holderHIKMA PHARMACEUTICALS USA INC
FDA applicationANDA080352 (ANDA)
Labeler code00054
First marketedMar 2020
Product typeHuman Prescription Drug
Portfolio726 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Very long sections are excerpted here and marked; the full text is on DailyMed (linked in the sources below). Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ~2 min read ▾

INDICATIONS Prednisone tablets are indicated in the following conditions: 1. Endocrine Disorders Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance) Congenital adrenal hyperplasia Hypercalcemia associated with cancer Nonsuppurative thyroiditis 2. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: Psoriatic arthritis Rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy) Ankylosing spondylitis Acute and subacute bursitis Acute nonspecific tenosynovitis Acute gouty arthritis Post-traumatic osteoarthritis Synovitis of osteoarthritis Epicondylitis 3.

Collagen Diseases During an exacerbation or as maintenance therapy in selected cases of: Systemic lupus erythematosus Systemic dermatomyositis (polymyositis) Acute rheumatic carditis 4. Dermatologic Diseases Pemphigus Bullous dermatitis herpetiformis Severe erythema multiforme (Stevens-Johnson syndrome) Exfoliative dermatitis Mycosis fungoides Severe psoriasis Severe seborrheic dermatitis 5. Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment: Seasonal or perennial allergic rhinitis Bronchial asthma Contact dermatitis Atopic dermatitis Serum sickness Drug hypersensitivity reactions 6.

Ophthalmic Diseases Severe acute and chronic allergic and inflammatory processes involving the eye and its adnexa such as: Allergic corneal marginal ulcers Herpes zoster ophthalmicus Anterior segment inflammation Diffuse posterior uveitis and choroiditis Sympathetic ophthalmia Allergic conjunctivitis Keratitis Chorioretinitis Optic neuritis Iritis and iridocyclitis 7. Respiratory Diseases Symptomatic sarcoidosis Loeffler’s syndrome not manageable by other means Berylliosis Fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy Aspiration pneumonitis 8.

Hematologic Disorders Idiopathic thrombocytopenic purpura in adults Secondary thrombocytopenia in adults Acquired (autoimmune) hemolytic anemia Erythroblastopenia (RBC anemia) Congenital (erythroid) hypoplastic anemia 9. Neoplastic Diseases For palliative management of: Leukemias and lymphomas in adults Acute leukemia of childhood 10. Edematous States To induce a diuresis or remission of proteinuria in the nephrotic syndrome, without uremia, of the idiopathic type or that due to lupus erythematosus.

11. Gastrointestinal Diseases To tide the patient over a critical period of the disease in: Ulcerative colitis Regional enteritis 12. Nervous System Acute exacerbations of multiple sclerosis 13.

Miscellaneous Tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy Trichinosis with neurologic or myocardial involvement

⏱️ Dosage and Administration ~3 min read ▾

DOSAGE AND ADMINISTRATION The initial dosage of prednisone may vary from 5 mg to 60 mg of prednisone per day depending on the specific disease entity being treated. In situations of less severity lower doses will generally suffice while in selected patients higher initial doses may be required. The initial dosage should be maintained or adjusted until a satisfactory response is noted.

If after a reasonable period of time there is a lack of satisfactory clinical response, prednisone should be discontinued and the patient transferred to other appropriate therapy. IT SHOULD BE EMPHASIZED THAT DOSAGE REQUIREMENTS ARE VARIABLE AND MUST BE INDIVIDUALIZED ON THE BASIS OF THE DISEASE UNDER TREATMENT AND THE RESPONSE OF THE PATIENT . After a favorable response is noted, the proper maintenance dosage should be determined by decreasing the initial drug dosage in small decrements at appropriate time intervals until the lowest dosage which will maintain an adequate clinical response is reached.

It should be kept in mind that constant monitoring is needed in regard to drug dosage. Included in the situations which may make dosage adjustments necessary are changes in clinical status secondary to remissions or exacerbations in the disease process, the patient’s individual drug responsiveness, and the effect of patient exposure to stressful situations not directly related to the disease entity under treatment; in this latter situation it may be necessary to increase the dosage of prednisone for a period of time consistent with the patient’s condition.

If after long-term therapy the drug is to be stopped, it is recommended that it be withdrawn gradually rather than abruptly. Multiple Sclerosis In the treatment of acute exacerbations of multiple sclerosis daily doses of 200 mg of prednisolone for a week followed by 80 mg every other day for 1 month have been shown to be effective. (Dosage range is the same for prednisone and prednisolone.) ADT ® (Alternate Day Therapy) ADT is a corticosteroid dosing regimen in which twice the usual daily dose of corticoid is administered every other morning.

The purpose of this mode of therapy is to provide the patient requiring long-term pharmacologic dose treatment with the beneficial effects of corticoids while minimizing certain undesirable effects, including pituitary-adrenal suppression, the Cushingoid state, corticoid withdrawal symptoms, and growth suppression in children. The rationale for this treatment schedule is based on two major premises: (a) the anti-inflammatory or therapeutic effect of corticoids persists longer than their physical presence and metabolic effects and (b) administration of the corticosteroid every other morning allows for re-establishment of more nearly normal hypothalamic-pituitary-adrenal (HPA) activity on the off-steroid day.

A brief review of the HPA physiology may be helpful in understanding this rationale. Acting primarily through the hypothalamus a fall in free cortisol stimulates the pituitary gland to produce increasing amounts of corticotropin (ACTH) while a rise in free cortisol inhibits ACTH secretion. Normally the HPA system is characterized by diurnal (circadian) rhythm.

Serum levels of ACTH rise from a low point about 10 pm to a peak level about 6 am. Increasing levels of ACTH stimulate adrenocortical activity resulting in a rise in plasma cortisol with maximal levels occurring between 2 am and 8 am. This rise in cortisol dampens ACTH production and in turn adrenocortical activity.

There is a gradual fall in plasma corticoids during the day with lowest levels occurring about midnight. The diurnal rhythm of the HPA axis is lost in Cushing’s disease, a syndrome of adrenocortical hyperfunction characterized by obesity with centripetal fat distribution, thinning of the skin with easy bruisability, muscle wasting with weakness, hypertension, latent diabetes, osteoporosis, electrolyte imbalance, etc. The same clinical findings of hyperadrenocorticism may be noted during l… [Excerpted — this section continues on DailyMed.]

⛔ Contraindications 9 words ▾

CONTRAINDICATIONS Systemic fungal infections and known hypersensitivity to components.

⚠️ Warnings ~2 min read ▾

WARNINGS In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. Immunosuppression and Increased Risk of Infection Corticosteroids, including prednisone, suppress the immune system and increase the risk of infection with any pathogen, including viral, bacterial, fungal, protozoan, or helminthic pathogens. Corticosteroids can: • Reduce resistance to new infections • Exacerbate existing infections • Increase the risk of disseminated infections • Increase the risk of reactivation or exacerbation of latent infections • Mask some signs of infection Corticosteroid-associated infections can be mild but can be severe and at times fatal.

The rate of infectious complications increases with increasing corticosteroid dosages. Monitor for the development of infection and consider prednisone withdrawal or dosage reduction as needed. Tuberculosis If prednisone is used to treat a condition in patients with latent tuberculosis or tuberculin reactivity, reactivation of tuberculosis may occur.

Closely monitor such patients for reactivation. During prolonged prednisone therapy, patients with latent tuberculosis or tuberculin reactivity should receive chemoprophylaxis. Varicella Zoster and Measles Viral Infections Varicella and measles can have a serious or even fatal course in non-immune patients taking corticosteroids, including prednisone.

In corticosteroid-treated patients who have not had these diseases or are non-immune, particular care should be taken to avoid exposure to varicella and measles: • If a prednisone-treated patient is exposed to varicella, prophylaxis with varicella zoster immune globulin may be indicated. If varicella develops, treatment with antiviral agents may be considered. • If a prednisone-treated patient is exposed to measles, prophylaxis with immunoglobulin may be indicated. Hepatitis B Virus Reactivation Hepatitis B virus reactivation can occur in patients who are hepatitis B carriers treated with immunosuppressive dosages of corticosteroids, including prednisone.

Reactivation can also occur infrequently in corticosteroid-treated patients who appear to have resolved hepatitis B infection. Screen patients for hepatitis B infection before initiating immunosuppressive (e.g., prolonged) treatment with prednisone. For patients who show evidence of hepatitis B infection, recommend consultation with physicians with expertise in managing hepatitis B regarding monitoring and consideration for hepatitis B antiviral therapy.

Fungal Infections Corticosteroids, including prednisone, may exacerbate systemic fungal infections; therefore, avoid prednisone use in the presence of such infections unless prednisone is needed to control drug reactions. For patients on chronic prednisone therapy who develop systemic fungal infections, prednisone withdrawal or dosage reduction is recommended. Amebiasis Corticosteroids, including prednisone, may activate latent amebiasis.

Therefore, it is recommended that latent amebiasis or active amebiasis be ruled out before initiating prednisone in patients who have spent time in the tropics or patients with unexplained diarrhea. Strongyloides Infestation Corticosteroids, including prednisone, should be used with great care in patients with known or suspected Strongyloides (threadworm) infestation. In such patients, corticosteroid-induced immunosuppression may lead to Strongyloides hyperinfection and dissemination with widespread larval migration, often accompanied by severe enterocolitis and potentially fatal gram-negative septicemia.

Cerebral Malaria Avoid corticosteroids, including prednisone, in patients with cerebral malaria. Kaposi’s Sarcoma Kaposi’s sarcoma has been reported to occur in patients receiving corticosteroid therapy, most often for chronic conditions. Discontinuation of corticosteroids may result in clinical improvement of Kaposi’s sarcoma.

Usage in pregnancy Si… [Excerpted — this section continues on DailyMed.]

🤒 Adverse Reactions 173 words ▾

ADVERSE REACTIONS Fluid and Electrolyte Disturbances Sodium retention Fluid retention Congestive heart failure in susceptible patients Potassium loss Hypokalemic alkalosis Hypertension Musculoskeletal Muscle weakness Steroid myopathy Loss of muscle mass Osteoporosis Tendon rupture, particularly of the Achilles tendon Vertebral compression fractures Aseptic necrosis of femoral and humeral heads Pathologic fracture of long bones Gastrointestinal Peptic ulcer with possible perforation and hemorrhage Pancreatitis Abdominal distention Ulcerative esophagitis Dermatologic Impaired wound healing Thin fragile skin Petechiae and ecchymoses Facial erythema Increased sweating May suppress reactions to skin tests Metabolic Negative nitrogen balance due to protein catabolism Neurological Increased intracranial pressure with papilledema (pseudotumor cerebri) usually after treatment Convulsions Vertigo Headache Endocrine Menstrual irregularities Development of Cushingoid state Secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in trauma, surgery or illness Suppression of growth in children Decreased carbohydrate tolerance Manifestations of latent diabetes mellitus Increased requirements for insulin or oral hypoglycemic agents in diabetics Ophthalmic Posterior subcapsular cataracts Increased intraocular pressure Glaucoma Exophthalmos Additional Reactions Urticaria and other allergic, anaphylactic or hypersensitivity reactions

📦 How Supplied / Storage and Handling 166 words ▾

HOW SUPPLIED PredniSONE Tablets, USP 5 mg – White to off-white, round, biconvex tablet; scored on one side and product identification “54 [above] 612” debossed on the other side. NDC 0054-9828-25: Bottle of 100 Tablets NDC 0054-9828-31: Bottle of 1,000 Tablets 10 mg – White to off-white, round, biconvex tablet; scored on one side and product identification “54 [above] 899” debossed on the other side. NDC 0054-9817-25: Bottle of 100 Tablets NDC 0054-9817-29: Bottle of 500 Tablets 20 mg – White to off-white, round, biconvex tablet; scored on one side and product identification “54 [above] 760” debossed on the other side.

NDC 0054-9818-25: Bottle of 100 Tablets NDC 0054-9818-29: Bottle of 500 Tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Dispense in a tight, child-resistant container as defined in the USP/NF. PROTECT FROM MOISTURE. Distributed by: Hikma Pharmaceuticals USA Inc.

Berkeley Heights, NJ 07922 Manufactured by: Hikma Pharmaceuticals PO Box 182400, Amman 11118 – Jordan 2INPRDST-E Revised January 2025 k02

📋 Description 112 words ▾

DESCRIPTION Prednisone is a glucocorticoid. Glucocorticoids are adrenocortical steroids, both naturally occurring and synthetic, which are readily absorbed from the gastrointestinal tract. Prednisone, USP is a white to partially white, crystalline powder.

It is very slightly soluble in water; slightly soluble in alcohol, chloroform, dioxane, and methanol. The chemical name for prednisone is 17,21-dihydroxypregna-1,4-dienne-3,11,20-trione. The structural formula is represented below: C 21 H 26 O 5 M.W.

358.44 Each tablet, for oral administration, contains 5, 10, or 20 mg of prednisone. Inactive Ingredients: PredniSONE Tablets, USP contain the following inactive ingredients: lactose monohydrate, magnesium stearate, microcrystalline cellulose, pregelatinized starch, sodium starch glycolate and stearic acid (5 mg only). Chemical Structure - Prednisone

⚠️ Precautions ~2 min read ▾

PRECAUTIONS General Precautions Drug-induced secondary adrenocortical insufficiency may be minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently.

There is an enhanced effect of corticosteroids on patients with hypothyroidism and in those with cirrhosis. Corticosteroids should be used cautiously in patients with ocular herpes simplex because of possible corneal perforation. The lowest possible dose of corticosteroid should be used to control the condition under treatment, and when reduction in dosage is possible, the reduction should be gradual.

Psychic derangements may appear when corticosteroids are used, ranging from euphoria, insomnia, mood swings, personality changes, and severe depression, to frank psychotic manifestations. Also, existing emotional instability or psychotic tendencies may be aggravated by corticosteroids. Aspirin should be used cautiously in conjunction with corticosteroids in hypoprothrombinemia.

Steroids should be used with caution in nonspecific ulcerative colitis, if there is a probability of impending perforation, abscess or other pyogenic infection; diverticulitis; fresh intestinal anastomoses; active or latent peptic ulcer; renal insufficiency; hypertension; osteoporosis; and myasthenia gravis. Growth and development of infants and children on prolonged corticosteroid therapy should be carefully observed. Although controlled clinical trials have shown corticosteroids to be effective in speeding the resolution of acute exacerbations of multiple sclerosis, they do not show that corticosteroids affect the ultimate outcome or natural history of the disease.

The studies do show that relatively high doses of corticosteroids are necessary to demonstrate a significant effect (see DOSAGE AND ADMINISTRATION ). Since complications of treatment with glucocorticoids are dependent on the size of the dose and the duration of treatment, a risk/benefit decision must be made in each individual case as to dose and duration of treatment and as to whether daily or intermittent therapy should be used. Convulsions have been reported with concurrent use of methylprednisolone and cyclosporin.

Since concurrent use of these agents results in a mutual inhibition of metabolism, it is possible that adverse events associated with the individual use of either drug may be more apt to occur.

📄 Package Label / Principal Display Panel 75 words ▾

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 5 mg Tablet NDC 0054- 9828 -25 100 Tablets PredniSONE Tablets, USP 5 mg 5 mg, 100 count bottle label

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 10 mg Tablet NDC 0054- 9817 -25 100 Tablets PredniSONE Tablets, USP 10 mg 10 mg, 100 count bottle label

PACKAGE/LABEL PRINCIPAL DISPLAY PANEL – 20 mg Tablet NDC 0054- 9818 -25 100 Tablets PredniSONE Tablets, USP 20 mg 20 mg, 100 count bottle label

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
33.8K
Units reimbursed last 4 qtrs
953.6K
Gross reimbursed last 4 qtrs
$271.9K
Avg / prescription
$8.04
Avg / unit
$0.2851
Latest quarter Q1 2026
8.4KRx
Medicaid pays / ea
$0.2851
gross reimbursed
vs
NADAC / ea
$0.0533
acquisition cost
=
Spread
+$0.2318
+435% vs cost
What Medicaid paid per ea (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
36% FFS 64% MCO
Fee-for-service · 12,191 Rx Managed care · 21,627 Rx
State Medicaid map
Alaska: 8,637 units · 1,178 per 100k residents AK Maine: 9,551 units · 685 per 100k residents ME Washington: 146,151 units · 1,871 per 100k residents WA Idaho: 15,736 units · 801 per 100k residents ID Montana: 19,785 units · 1,748 per 100k residents MT North Dakota: no data reported ND Minnesota: 7,963 units · 139 per 100k residents MN Wisconsin: 39,668 units · 671 per 100k residents WI Michigan: 29,062 units · 290 per 100k residents MI New York: 36,488 units · 186 per 100k residents NY Vermont: 4,295 units · 664 per 100k residents VT New Hampshire: 7,725 units · 551 per 100k residents NH Oregon: 88,772 units · 2,097 per 100k residents OR Nevada: 12,039 units · 377 per 100k residents NV Wyoming: 1,681 units · 288 per 100k residents WY South Dakota: 3,030 units · 330 per 100k residents SD Iowa: 6,953 units · 217 per 100k residents IA Illinois: 54,847 units · 437 per 100k residents IL Indiana: 14,387 units · 210 per 100k residents IN Ohio: 21,253 units · 180 per 100k residents OH Pennsylvania: 21,038 units · 162 per 100k residents PA New Jersey: 12,933 units · 139 per 100k residents NJ Massachusetts: 10,530 units · 150 per 100k residents MA California: 93,175 units · 239 per 100k residents CA Utah: 2,377 units · 69.6 per 100k residents UT Colorado: 24,337 units · 414 per 100k residents CO Nebraska: 9,351 units · 473 per 100k residents NE Missouri: 24,600 units · 397 per 100k residents MO Kentucky: 17,836 units · 394 per 100k residents KY West Virginia: 13,209 units · 746 per 100k residents WV Virginia: 8,220 units · 94.3 per 100k residents VA Maryland: 20,437 units · 331 per 100k residents MD Connecticut: 5,766 units · 159 per 100k residents CT Rhode Island: 1,730 units · 158 per 100k residents RI Arizona: 42,643 units · 574 per 100k residents AZ New Mexico: 11,741 units · 555 per 100k residents NM Kansas: 2,403 units · 81.7 per 100k residents KS Arkansas: 13,293 units · 433 per 100k residents AR Tennessee: 8,139 units · 114 per 100k residents TN North Carolina: 5,814 units · 53.7 per 100k residents NC South Carolina: 1,371 units · 25.5 per 100k residents SC Delaware: 4,385 units · 425 per 100k residents DE Oklahoma: 14,345 units · 354 per 100k residents OK Louisiana: 10,221 units · 223 per 100k residents LA Mississippi: 6,444 units · 219 per 100k residents MS Alabama: 3,108 units · 60.8 per 100k residents AL Georgia: 2,901 units · 26.3 per 100k residents GA D.C.: 3,973 units · 585 per 100k residents DC Hawaii: 4,561 units · 318 per 100k residents HI Texas: 19,817 units · 65.0 per 100k residents TX Florida: 4,866 units · 21.5 per 100k residents FL
Units reimbursed · per 100k residents
21.52,097
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Oregon 2,097 /100k
2 Washington 1,871 /100k
3 Montana 1,748 /100k
4 Alaska 1,178 /100k
5 Idaho 801 /100k
6 West Virginia 746 /100k
7 Maine 685 /100k
8 Wisconsin 671 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
500 tablets00054-9817-29 54,796 Rx · $475,039
100 tablets this page00054-9817-25 33,818 Rx · $271,881
Drug total (last 4 qtrs): 88,614 Rx · 2,322,586 units · $746,920 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Prednisone — the program that covers self-administered drugs. 17 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Prednisone. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$16.74M
Claims incl. refills
4.1M
Beneficiaries
3M
Spend / beneficiary
$5.57
Spend / claim
$4.04
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.